The Ministry of Health confirmed this Friday that it is investigating a case of Guillain Barré that could be linked to the application of the vaccine against COVID-19.
The case, according to the Health authorities, was classified as conditional due to the pathologies presented by the patient and that could have triggered the condition.
Guillain Barré syndrome is a disorder in which the body’s immune system attacks itself by mistake. This causes inflammation of nerves and with this muscle weakness or paralysis, among other symptoms.
Similarly, a case of myocarditis (inflammation of the heart) classified as probable was reported given the potential relationship between the symptom and the administration of the vaccine; as well as phlebitis (inflammation of the veins) which was classified as possible, since it may be due to other factors or drugs consumed by the patient.
“The patients who presented myocarditis and phlebitis evolved satisfactorily and are recovered, the patient who presented Guillain Barré is stable,” said Salud.
The authorities assure that of the total number of people vaccinated against COVID-19 only 0.67% have presented some type of event that could be attributable to vaccination or immunization, with the majority of cases in women (73%) and within the age range between 30 and 39 years (42%).
This means that of the 150,000 doses applied, 1,653 have reported Events Supposedly Attributable to Vaccination and Immunization (ESAVI).
Xiomara Vega, coordinator of the National Center for Pharmacovigilance, stressed that “most of the notifications include several ESAVIs, for example, a person may have had pain at the injection site and fever after the administration of the vaccine.”
Nervous system disorders (mostly headache) have been the most reported events, followed by application site disorders (local pain), general disorders (fatigue / tiredness, fever / low-grade fever, chills), skin disorders and appendages such as skin rash and / or rash as well as itching and disorders of the musculoskeletal system.
An ESAVI was also received that meets the definition of an anaphylactic reaction case (sudden and generalized allergic reaction), however, since it entered on February 26, 2021 and it is under investigation, it will be included in the report of the March 2021, once the investigation is concluded.
–
